Form 4: KalVista COO Granted 49,000 Restricted Stock Units

KalVista Pharmaceuticals' Chief Operations Officer, Bilal Arif, was granted 49,000 Restricted Stock Units, vesting quarterly starting May 22, 2026.

Summary

• Bilal Arif, Chief Operations Officer of KalVista Pharmaceuticals, Inc. (KALV), was granted 49,000 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
• The transaction date for this grant was January 16, 2026.
• Vesting for these RSUs will occur quarterly, with 1/16th of the total shares vesting on each quarterly anniversary of the Vesting Commencement Date, starting May 22, 2026.
• The vesting is contingent upon the grantee's continued service to the company.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects standard executive compensation practices, aligning management's interests with shareholders and aiding in executive retention. It does not, however, provide direct operational or financial performance insights.

Positives

• The grant of Restricted Stock Units aligns the Chief Operations Officer's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This compensation structure serves as a retention mechanism, incentivizing the executive to remain with the company through the vesting period.

Negatives

• The future settlement of these RSUs will result in a minor dilution of existing shareholder equity when the shares are issued.

Risks

• The value of the granted Restricted Stock Units is subject to the future market price of KalVista Pharmaceuticals' common stock.
• The RSUs are subject to forfeiture if the grantee's service to the company terminates before the vesting schedule is complete.

Future Outlook

The grant of Restricted Stock Units indicates a long-term compensation strategy for the Chief Operations Officer, with future share issuance contingent on continued service and stock performance through the vesting period commencing in May 2026.

Industry Context

The grant of Restricted Stock Units is a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to attract, retain, and motivate key personnel by aligning their financial interests with the long-term success of the company.

Comparison to Industry Standards

• The use of Restricted Stock Units as a component of executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to compensation strategies at companies like BioNTech, Moderna, or Regeneron, which frequently utilize equity awards to incentivize leadership.
• The vesting schedule, typically over several years, is also consistent with industry norms aimed at long-term retention and performance alignment.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon RSU settlement, but also increased alignment of executive interests with shareholder value.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• The Restricted Stock Units will begin vesting on May 22, 2026, with subsequent quarterly vesting periods.
• The company will issue common stock to Bilal Arif upon the settlement of vested RSUs.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Beneficial Ownership, Corporate Governance